A031702 (Penile Cohort Suspended 3/13/20/ Miscellaneous GU Tract Variants Cohort suspended 7/20/20/ Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21/ Adenocarcinoma of the Bladder Cohort Closed 11/9/20/ Renal Medullary Cohort suspended 6/23/21))
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.